洛索洛芬与罗非昔布对照治疗膝骨关节炎57例

目的：对比洛索洛芬和特异性环氧化酶—2(COX—2)抑制剂罗非昔布治疗膝骨关节炎(0A)的疗效和安全性。方法：入选62例OA患者，随机口服洛索洛芬(n＝29)，每次60mg，tid或罗非昔布(n=33)每次25mg，qd，疗程4周。分别在治疗前后进行疗效和安全性评估。结果：共57例(洛索洛芬组26例，罗非昔布组31例)完成疗程，2组对膝0A休息时痛、活动痛、关节活动度、关节压痛和患者总评定等各项指标的有效率均超过70％。在对各指标的改善上2组药物相比差异均无显著性(P＞0．05)。2d内起效者洛索洛芬组显著高于罗非昔布组(59．1％对25．9％．P＝0．019)。洛索洛芬和罗非昔布的不良反应发生率相当(30．8％对48．4％，P＞0．05)，而罗非昔布组的口腔溃疡发生率(16．1％)显著高于洛索洛芬组(0．0％，P=0．019)。结论：洛索洛芬与罗非昔布均有较强的消炎镇痛作用，而且起效快，不良反应轻，依从性较好。     

国产美洛昔康治疗类风湿关节炎的疗效观察

目的：观察国产美洛昔康对类风湿关节炎（RA）的疗效和安全性。方法：选取RA病人40例，试验组口服国产美洛昔康7.5mg，2次／d；对照组口服双氯酚酸钠50mg,2次／d。治疗时间为28d。分别观察治疗前后临床指标和炎性实验指标的变化及不良反应。结果：两组治疗前后组内比较在休息痛、晨僵、关节肿胀指数、关节压痛指数、握力、关节功能、日常生活能力、血沉、C－反应蛋白等方面均有显性差异；而组间比较均无显性差异。两组有效率无显性差异，而不良反应发生率国产美洛昔康组较低。结论：国产美洛昔康对RA的疗效与双氯酚酸钠相当，不良反应低。     

2种疗效判断标准对洛索洛芬治疗类风湿关节炎的评价

目的 :国内、美国风湿病学会 (ACR) 2种疗效判断标准评价洛索洛芬 (loxoprofen)治疗类风湿关节炎 (RA)的疗效及不良反应。方法 :选择 5 0例 ,年龄 (4 8±s 13)a ,4 0～ 69aRA活动期病人 (男女不限 ) ,口服洛索洛芬 60mg ,tid× 4wk ,比较用药前后关节压痛数、关节肿胀数、血沉、C反应蛋白等临床及实验室指标的变化 ,用国内、ACR不同疗效判断标准评价洛索洛芬治疗RA的疗效及不良反应。结果 :洛索洛芬治疗RA的总有效率达 74 %(国内标准 )和 80 % (ACR标准 ) ,2种疗效判断标准无显著差异 ,各项临床及实验室指标均有显著改善 ,不良反应发生率 10 % ,未出现危及生命的不良反应。结论 :洛索洛芬治疗RA安全、有效     

复方玄驹胶囊联合洛索洛芬钠治疗骨关节炎的临床研究

目的 探讨复方玄驹胶囊联合洛索洛芬钠治疗骨关节炎的临床效果.方法 选取2019年12月—2020年11月天津中医药大学第一附属医院收治的126例骨关节炎患者,随机分成对照组(63例)和治疗组(63例).对照组口服洛索洛芬钠片,60 mg/次,3次/d.在对照组基础上,治疗组口服复方玄驹胶囊,1.26 g/次,3次/d....     

骨康胶囊联合洛索洛芬钠治疗膝关节骨性关节炎的临床研究

目的观察骨康胶囊联合洛索洛芬钠片治疗膝关节骨性关节炎的临床疗效。方法选取2016年11月—2018年7月荆州市中医医院收治的142例膝关节骨性关节炎患者作为研究对象,采用双盲法将所有患者随机分为对照组和治疗组,每组各71例。对照组口服洛索洛芬钠片,60mg/次,3次/d。治疗组在对照组的基础上口服用骨康胶囊,3粒/次,3次/d。两组患者均持续治疗1个月。观察两组患者的临床疗效,比较两组治疗前后的Lysholm膝关节评分、骨关节指数评分(WOMAC)、视觉模拟评分(VAS)和血清学指标。结果治疗后,对照组和治疗组的临床有效率分别为84.51%、92.95%,两组比较差异具有统计学意义(P0.05)。治疗后,两组Lysholm评分显著升高,WOMAC、VAS评分显著降低(P0.05);治疗后,治疗组上述评分均显著优于对照组(P0.05)。治疗后,两组血清肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)水平明显降低,转化生长因子-β1(TGF-β1)水平明显升高(P0.05);治疗后,治疗组血清学指标明显优于对照组(P0.05)。结论骨康胶囊联合洛索洛芬钠片治疗膝关节骨性关节炎疗效确切,可减轻患者疼痛和炎症因子水平,改善关节活动度,具有较好的临床推广应用价值。     

洛索洛芬钠治疗强直性脊柱炎的疗效与安全性评价

目的：观察洛索洛芬钠（乐松）治疗强直性脊柱炎（AS）的疗效与安全性，方法：选择52例活动性AS患者，口服洛索洛芬钠，60mg,tid。分别在0周和第4周末进行疗效和安全性评价。结果：可评价患者共50例，2例脱落，经过4周的治疗，乐松对AS患者的总效率为92．42％，其中对各主要疗效指标均有明显改善（P＜0．05）。耐受性较好，不良反应发生率仅为8％，主要为轻中度的胃肠道不适，无严重或危豚生命的不良反应发生。结论：洛索洛芬钠其抗炎镇痛作用对活动性AS的疼痛与功能受限有较好的改善，安全性较好。     

痹祺胶囊联合洛索洛芬钠治疗类风湿性关节炎的临床研究

目的探讨痹祺胶囊联合洛索洛芬钠治疗类风湿性关节炎患者的临床效果。方法选取2015年3月—2018年3月天津医科大学总医院滨海医院和天津医院诊治类风湿性关节炎患者104例,根据患者用药差别分成对照组和治疗组,每组各52例。对照组患者口服洛索洛芬钠片,60 mg/次,3次/d。治疗组患者在对照组基础上口服痹祺胶囊,1.2 g/次,3次/d。两组患者连续治疗3个月。观察两组患者临床疗效,同时比较治疗前后两组患者压痛和肿胀关节数及症状积分,血清基质金属蛋白酶3(MMP-3)和骨特异性碱性磷酸酶(B-ALP)水平及红细胞沉降(ESR)。结果治疗后,对照组的总有效率为82.69%,显著低于治疗组的96.15%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者压痛关节数、肿胀关节数及症状积分较治疗前均显著减少(P0.05),且治疗组压痛关节数、肿胀关节数及症状积分明显少于对照组(P0.05)。治疗后,两组血清MMP-3水平、ESR均显著降低(P0.05),血清B-ALP水平显著升高(P0.05),且治疗组MMP-3、ESR和B-ALP水平明显好于对照组(P0.05)。结论痹祺胶囊联合洛索洛芬钠片治疗类风湿性关节炎能够显著改善患者临床症状和生化指标水平,安全性高,具有一定的临床推广应用价值。     

藤黄健骨丸联合洛索洛芬钠治疗膝骨关节炎的临床研究

目的探讨藤黄健骨联合洛索洛芬钠治疗膝骨关节炎的临床疗效和安全性。方法选取2016年6月—2017年6月在河南省洛阳正骨医院诊治膝骨关节炎患者152例,随机分成对照组(76例)和治疗组(76例)两组。对照组患者口服洛索洛芬钠片,1片/次,3次/d;治疗组患者在对照组基础上口服藤黄健骨丸,1丸/次,2次/d。两组患者均连续治疗6周。观察两组患者临床疗效,同时比较治疗前后两组患者骨关节炎指数、KSS评分和15 m行走时间,血清白细胞介素-1β(IL-1β)、软骨寡聚基质蛋白(COMP)和前列腺素E2(PGE2)水平及不良反应。结果治疗后,对照组临床有效率为86.84%,显著低于治疗组的97.37%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者骨关节炎指数和15 m行走时间均显著下降(P0.05),KSS评分显著升高(P0.05),且治疗组患者骨关节炎指数、KSS评分和15 m行走时间均明显优于对照组(P0.05)。治疗后,两组患者血清IL-1β、COMP和PGE2水平均显著下降(P0.05),且治疗组患者血清IL-1β、COMP和PGE2水平明显低于对照组(P0.05)。治疗期间,治疗组药物不良反应发生率为2.63%,显著低于对照组的13.16%,两组比较差异具有统计学意义(P0.05)。结论藤黄健骨联合洛索洛芬钠治疗膝骨关节炎疗效显著、安全性高,具有一定的临床推广应用价值。     

双嘧达莫、叶酸、乳酸菌素片治疗婴幼儿秋季腹泻疗效观察

目的探讨潘生丁、叶酸、乳酸菌素片治疗婴幼儿秋季腹泻的疗效。方法将临床确诊的200例腹泻患儿随机分为潘生丁、叶酸、乳酸菌素片联合治疗组及对照组各100例，两组病情分度经统计学处理差异无显著性（P〉0．05），具有可比性。两组均视病情给予补液、纠正酸中毒及对症治疗。治疗组在此基础上口服双嘧达莫2～3mg／（kg·次），3次／d口服；叶酸5mg／次，3次／d口服；乳酸菌素片1／2～1片／次，3次／d口服。对照组口服小儿新诺明、酵母片。结果治疗组与对照组的显效率、总有效率、发热消失天数、止泻天数、平均治愈天数疗效经统计学分析，差异有显著性（P〈0．01）。结论双嘧达莫、叶酸、乳酸菌素片联合治疗婴幼儿秋季腹泻是安全、有效的药物，而且药源广，价格低廉，值得临床推广应用。     

美洛昔康与双氯酚酸钠治疗骨关节炎疗效比较

目的:评价美洛昔康与双氯酚酸钠治疗骨关节炎(OA)患者的临床疗效和不良反应.方法:采用随机、平行对照研究.试验组(40例)给予口服美洛昔康7.5 mg,1次/d;对照组(41例)给予口服双氯酚酸钠0.1 g,1次/d,疗程均为4周.结果:总体疗效试验组为90.00%,对照组为90.24%,两组无显著性差异(P＞0.05);不良反应发生率试验组为10.00%,对照组为29.27%,两组有显著性差异(P＜0.05).结论:美洛昔康与双氯酚酸钠对OA都具有明显抗炎镇痛作用,但美洛昔康的不良反应较少.     

尼美舒利治疗类风湿关节炎和骨性关节炎的临床研究

目的：观察国产尼美舒利对类风湿关节炎（ＲＡ）和骨性关节炎（ＯＡ）的疗效和安全性。方法：选取ＲＡ患者５９ 例和ＯＡ患者４４ 例。ｐｏ 尼美舒利片１００ ｍｇ,ｂｉｄ;对照组ｐｏ 布洛芬缓释胶囊３００ｍｇ,ｂｉｄ。治疗时间为４ｗｋ。分别观察治疗前后临床指标和炎性实验指标的变化。结果：尼美舒利治疗ＲＡ４ｗｋ 后,疼痛程度、压痛关节数、关节压痛指数、关节肿胀指数、握力、晨僵时间、血沉均显著改善。对ＲＡ的总有效率为８３．３％ 。治疗ＯＡ４ｗｋ 后,膝关节活动痛、１５ｍ 行走时间、日常活动能力及病人综合评估均有显著改善。对ＯＡ的总有效率为７５．０％ 。其不良反应总发生率为１９．２％ , 以胃肠道反应为常见（９．６％）。尼美舒利对ＲＡ和ＯＡ的疗效及不良反应的发生率与布洛芬相比均无显著性差异。结论：尼美舒利对ＲＡ和ＯＡ的疗效及不良反应的发生率均与布洛芬相当。     

国产尼美舒利治疗类风湿关节炎和骨关节炎

观察国产尼美美舒利对类风湿关节炎和骨关节炎（ＯＡ）的疗效和安全性。方法：选取ＲＡ患者１１２例和ＯＡ患者９１例。口服尼美舒利片１００ｍｇ,ｂｉｄ;对照组口服布洛芬缓释胶囊３００ｍｇ,ｂｉｄ。治疗时间为４周。分别观察治疗前后临床指标和炎性实验指标的变化。     

Antipyretic and analgesic effects of zaltoprofen for the treatment of acute upper respiratory tract infection: verification of a noninferiority hypothesis using loxoprofen sodium

A multicenter, placebo-controlled, double-dummy, randomized, parallel-group, double-blind study was conducted to verify the hypothesis of noninferiority for single-dose administration of zaltoprofen 160 mg, a nonsteroidal anti-inflammatory drug, compared with loxoprofen sodium 60 mg (loxoprofen), in terms of antipyretic and analgesic effects in patients with acute upper respiratory tract infection. The eligible 330 patients were assigned to one of 3 groups: zaltoprofen 160 mg, loxoprofen 60 mg and placebo. The analysis set consisted of 322 patients. Antipyretic effects were assessed by measuring body temperature, and analgesic effects were evaluated using a visual analog scale (VAS) for 4 h under the control of study staff. A detection kit for influenza virus A and B antigens was used to determine the presence of influenza virus infection. Compared with immediately before administration and with the placebo group, significant decreases in body temperature and summary VAS pain scores were noted in both the zaltoprofen and loxoprofen groups at 4 h after drug administration. Based on the degree of decrease in body temperature and the summary VAS pain scores up to 4 h after administration, noninferiority in terms of antipyretic and analgesic effects of zaltoprofen compared with those of loxoprofen was confirmed after single administration. Similar antipyretic and analgesic effects were also confirmed in influenza virus antigen-positive patients (73 patients). No clinical concerns were identified regarding safety. Zaltoprofen and loxoprofen are confirmed to be safe and useful for patients with acute upper respiratory tract infection, including those with influenza infection.     

精氨洛芬治疗膝骨关节炎有效性和安全性观察

目的：观察精氨洛芬治疗膝骨关节炎（OA）的疗效和安全性。方法：采用开放试验,观察30例膝OA患者应用精氨洛芬（400mg,tid）的疗效和安全性,疗程为14d。主要疗效指标为靶部位患者的总体评价（视觉模拟评分法,VAS）,次要疗效指标包括休息痛指数、活动痛指数、关节压痛指数、关节肿胀指数、医生总体评价和药物起效时间,并对不良事件进行统计记录。结果：治疗前患者的总体VAS评分为（6.62±1.52）,治疗后降低至（3.57±2.36）（P〈0.001）,除关节肿胀指数外的各次要疗效指标在治疗后也有不同程度改善（P〈0.01或P〈0.001）,总有效率为70.0%。不良事件发生率为16.7%,而且均是轻度。结论：精氨洛芬治疗膝骨关节炎有良好的止痛效果,安全性好。     

Clinical efficacy and tolerance of galactosoaminoglucuronoglycan sulfate in the treatment of osteoarthritis

An open design has been carried out by the authors comparing the efficacy and the tolerance of galactosoaminoglucuronoglycan sulfates (GAGs) with those of ibuprofen lysine in patients affected by osteoarthritis (OA). The experimental group included forty patients of both sexes, aged from 35 to 67 years, with diffuse OA. Ten patients were treated with GAGs administered orally (600-1200 mg/die) and ten patients with GAGs administered intramuscularly (50-100 mg/die); likewise for the ibuprofen therapy two subgroups were formed, such that ten patients were given the drug orally (1500-2500 mg/die) and ten patients had intramuscular therapy (400-800 mg/die). The treatment lasted 40 days. The parameters considered were: pain at rest, pain on pressure, pain on active movement and pain on passive movement. Tolerance was considered by carrying out some routinary laboratory tests and a careful clinical and anamnestic examination. At the end of the study, an improvement in all the clinical variables considered was found in both groups of patients, with no significant differences between the oral and the intramuscular administrations. With regard to tolerance, it must be noted that 10% of the patients in each of the two considered groups patients suffered from gastro-intestinal diseases (pain, nausea, pyrosis). The results achieved, therefore, confirm the efficacy and above all the good tolerance of GAGs in the treatment of OA, characteristics of particular importance for a drug designed for the therapy of a chronic pathology such as OA.     

The influence of ibuprofen,diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide

Summary In an open triple crossover study in 8 patients with essential hypertension, the possibility has been investigated of whether the blood pressure lowering effect of hydrochlorothiazide 50 mg once daily was attenuated by co-administration for 4 weeks of ibuprofen 400 mg t.i.d., diclofenac 25 mg t.i.d. or sulindac 200 mg b.i.d. Only a slight, statistically non-significant change was found, with the exception of a significant increase in systolic blood pressure after 4 weeks treatment with ibuprofen. There was considerable variation in the blood pressure response during treatment with all three NSAIDs, with slight rises in blood pressure in 13 out of 24 periods. Body weight increased significantly on treatment both with ibuprofen and diclofenac, whereas the increase on sulindac was less and was transient. No significant change was found in various biochemical parameters, including plasma electrolytes, plasma renin activity (PRA), aldosterone, albumin and creatinine, in haematocrit or in the 24-h urinary excretion of sodium and potassium. The sole exception was a decrease in PRA during ibuprofen treatment. From these observations it is concluded that ibuprofen and diclofenac differ from sulindac in their interaction with the diuretic action of hydrochlorothiazide. It appears that all three NSAIDs can safely be combined with hydrochlorothiazide in hypertensive patients, but blood pressure should be monitored carefully when an NSAID are added.     

Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients

Background  Chronic use of NSAIDs is associated with gastrointestinal (GI) toxicity that increases with age.
Aim  To evaluate the GI safety and therapeutic efficacy of ibuprofen chemically associated with phosphatidylcholine (PC) in osteoarthritic (OA) patients.
Methods  A randomized, double-blind trial of 125 patients was performed. A dose of 2400 mg/day of ibuprofen or an equivalent dose of ibuprofen-PC was administered for 6 weeks. GI safety was assessed by endoscopy. Efficacy was assessed by scores of analgesia and anti-inflammatory activity. Bioavailability of ibuprofen was pharmacokinetically assessed.
Results  Ibuprofen-PC and ibuprofen provided similar bioavailability/therapeutic efficacy. In the evaluable subjects, a trend for improved GI safety in the ibuprofen-PC group compared with ibuprofen that did not reach statistical significance was observed. However, in patients aged >55 years, a statistically significant advantage for ibuprofen-PC treatment vs. ibuprofen in the prevention of NSAID-induced gut injury was observed with increases in both mean Lanza scores and the risk of developing >2 erosions or an ulcer. Ibuprofen-PC was well tolerated with no major adverse events observed.
Conclusion  Ibuprofen-PC is an effective osteoarthritic agent with an improved GI safety profile compared with ibuprofen in older OA patients, who are most susceptible to NSAID-induced gastroduodenal injury.     

双氯芬酸钠缓释胶囊与布洛芬缓释胶囊治疗类风湿性关节炎比较

目的:比较双氯芬酸钠缓释胶囊和布洛芬缓释胶囊治疗类风湿性关节炎的疗效及安全性.方法:采用随机分组的对照方法,将168例患者分为治疗组86例,口服双氯芬酸钠缓释胶囊50 mg,bid,对照组82例,口服布洛芬缓释胶囊300 mg,tid,均以2周为1个疗程.结果:两药均能显著改善类风湿性关节炎的症状,治疗组和对照组总有效率分别为76.74%,63.41%(P＞0.05),显效率分别为56.98%,37.80%(P＜0.05).不良反应均较轻.结论:双氯芬酸钠缓释胶囊对类风湿性关节炎的疗效优于布洛芬缓释胶囊.